Liese Barbier

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Introduction Heart failure (HF) is a chronic, progressive condition in which the heart is unable to pump enough oxygen-rich blood to meet the body's needs and is characterized by symptoms such as dyspnoea, ankle swelling, decreased exercise capacity and fatigue.1, 2 The symptom burden for patients has been reported to be severe, resulting in high mortality rates, frequent hospitalizations, limitations in physical activities and reduced quality of life (QoL).2-4 Hence, HF remains a leading...

Abstract The monoclonal antibody trastuzumab (Herceptin®), which targets the human epidermal growth factor receptor 2 (HER2), is approved for the treatment of early breast and advanced breast and gastric cancer in which HER2 is overexpressed. Several biosimilar versions of trastuzumab are expected to enter the European market over the course of 2018 and 2019.